X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Fresenius Kabi Onco. with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs TEVA PHARMA (Israel) - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 FRESENIUS KABI ONCO.   TEVA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
TEVA PHARMA
Dec-13
FRESENIUS KABI ONCO./
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1762,658-   
Low Rs792,309-   
Sales per share (Unadj.) Rs37.71,525.2-  
Earnings per share (Unadj.) Rs5.195.3-  
Cash flow per share (Unadj.) Rs6.7218.6-  
Dividends per share (Unadj.) Rs083.41-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs42.51,694.2-  
Shares outstanding (eoy) m158.23848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.6 207.4%   
Avg P/E ratio x25.026.1 95.9%  
P/CF ratio (eoy) x18.911.4 166.6%  
Price / Book Value ratio x3.01.5 204.1%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m20,1352,105,694 1.0%   
No. of employees `0001.244.9 2.6%   
Total wages/salary Rs m7030-   
Avg. sales/employee Rs Th5,176.228,777.2 18.0%   
Avg. wages/employee Rs Th610.40-   
Avg. net profit/employee Rs Th699.61,797.7 38.9%   
INCOME DATA
Net Sales Rs m5,9631,293,392 0.5%  
Other income Rs m180-   
Total revenues Rs m5,9811,293,392 0.5%   
Gross profit Rs m1,430354,196 0.4%  
Depreciation Rs m258104,546 0.2%   
Interest Rs m-2625,404 -0.1%   
Profit before tax Rs m1,216224,246 0.5%   
Minority Interest Rs m01,019 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-147,205 0.0%   
Tax Rs m342-2,738 -12.5%   
Profit after tax Rs m80680,797 1.0%  
Gross profit margin %24.027.4 87.6%  
Effective tax rate %28.1-1.2 -2,304.6%   
Net profit margin %13.56.2 216.3%  
BALANCE SHEET DATA
Current assets Rs m5,102873,552 0.6%   
Current liabilities Rs m2,385761,812 0.3%   
Net working cap to sales %45.68.6 527.2%  
Current ratio x2.11.1 186.5%  
Inventory Days Days15091 165.2%  
Debtors Days Days11396 118.1%  
Net fixed assets Rs m5,148422,450 1.2%   
Share capital Rs m1583,184 5.0%   
"Free" reserves Rs m6,5560-   
Net worth Rs m6,7321,436,714 0.5%   
Long term debt Rs m952661,340 0.1%   
Total assets Rs m10,3882,955,816 0.4%  
Interest coverage x-45.89.8 -465.8%   
Debt to equity ratio x0.10.5 30.7%  
Sales to assets ratio x0.60.4 131.2%   
Return on assets %7.53.6 209.0%  
Return on equity %12.05.6 212.9%  
Return on capital %14.64.9 296.1%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Net fx Rs m3,5250-   
CASH FLOW
From Operations Rs m1,274206,100 0.6%  
From Investments Rs m-1,204-73,029 1.6%  
From Financial Activity Rs m-196-247,231 0.1%  
Net Cashflow Rs m-126-114,160 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare FRESENIUS KABI ONCO. With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare FRESENIUS KABI ONCO. With: VENUS REMEDIES  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS